Fresenius SE & Co. KGaA Stock Forecast for 2023 - 2025 - 2030
Updated on 06/08/2023
Fresenius SE & Co. KGaA Stock Forecast and Price Target
The average price target for Fresenius SE & Co. KGaA's stock of 32.50€ recently provided by four leading analysts would represent a 25% upside from its last closing price if reached. This potential increase is based on a high estimate of 92.00€ and a low estimate of 16.60€. If you are looking to invest in the stock, it's important to research and compare different companies.
25.00% Upside
Fresenius SE & Co. KGaA Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Price has seen a drop from 44.72€ to 43.55€ – a 2.62% decrease. According to 0 major analysts, Fresenius SE & Co. KGaA's Fair Value will fall by 0.31% in the next year, reaching 43.41€. Professionals believe that By 2030, Fresenius SE & Co. KGaA's Fair Value will fall to 43.38€– a 0.40% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$445.62 | $333.19 | -10.24% |
| NESN Stock Forecast | Nestlé | Outperform |
5
|
CHF111.10 | CHF122.48 | 8.01% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr967.50 | kr937.82 | 0.78% |
| ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | CHF384.23 | 24.32% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$39.09 | $47.96 | 34.69% |
Fresenius SE & Co. KGaA Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Revenue has grown, moving from 35.41€B to 37.52€B – an increase of 5.96%. According to 0 major analysts, Fresenius SE & Co. KGaA's Revenue will fall by 3.00% in the next year, reaching 36.39€B. Professionals believe that By 2030, Fresenius SE & Co. KGaA's Revenue will fall to 36.45€B– a 2.84% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.75k | £153.20 | -98.67% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$110.32 | $99.57 | 6.96% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
Fresenius SE & Co. KGaA Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Dividend per Share has seen an increase, rising from 0.84€ to 0.92€. This represents a growth of 9.52%. In the next year, 0 analysts estimate that Fresenius SE & Co. KGaA's Dividend per Share will decrease by 4.42%, reaching 0.88€. According to professional forecasts, in 2030, Fresenius SE & Co. KGaA's Dividend per Share will decrease by 4.14%, reaching 0.88€.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$100.79 | $121.64 | 24.02% |
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | 108.44€ | 20.72% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$249.50 | $284.07 | 10.22% |
Fresenius SE & Co. KGaA Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Free Cash Flow for Fresenius SE & Co. KGaA has grown by 67.27%, going from 1.83€B to 3.06€B. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach 3.21€B – an increase of 4.96%. Over the next nine years, experts anticipate that Free Cash Flow growth for Fresenius SE & Co. KGaA will be 5.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.38k | £16.95 | -98.83% |
| BN Stock Forecast | Danone | Hold |
18
|
49.65€ | 55.47€ | 11.78% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
18
|
Rp1.01k | Rp845.39 | 2.61% |
Fresenius SE & Co. KGaA Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Net Income has fallen from 1.88€B to 1.82€B – a 3.45% decrease. According to 0 analysts, Fresenius SE & Co. KGaA's Net Income will fall by 0.64% in the next year, reaching 1.81€B. Professionals believe that By 2030, Fresenius SE & Co. KGaA's Net Income will fall to 1.80€B – a 0.75% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.34 | $60.73 | 40.30% |
| 4543 Stock Forecast | Terumo | Outperform |
18
|
¥3.61k | ¥0.00 | 38.58% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
18
|
Rp4.27k | Rp5.47k | 15.97% |
Fresenius SE & Co. KGaA EBITDA Forecast for 2023 - 2025 - 2030
Fresenius SE & Co. KGaA's EBITDA has grown in the last two years, jumping from 6.02€B to 6.83€B – an increase of 13.32%. 0 analysts predict Fresenius SE & Co. KGaA's EBITDA will decrease by 7.20% in the next year, reaching 6.33€B. By 2030, professionals predict that Fresenius SE & Co. KGaA's EBITDA will decrease by 6.73%, to 6.37€B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GRF Stock Forecast | Grifols | Outperform |
18
|
11.36€ | 27.25€ | 86.62% |
| 002422 Stock Forecast | Sichuan Kelun Pharmaceutical | Outperform |
16
|
¥29.95 | ¥0.00 | -26.54% |
| PRGO Stock Forecast | Perrigo | Buy |
16
|
$33.65 | $47.75 | 41.16% |
Fresenius SE & Co. KGaA EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's EBIT has decreased from 4.57€B to 4.16€B – a 9.04% drop. In the next year, analysts are expecting an increase in EBIT, predicting it will reach 4.40€B – an increase of 5.79%. The Fresenius SE & Co. KGaA forecast is for EBIT to reach 4.40€B or grow by 5.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£1.84k | £29.33 | -98.50% |
| ICUI Stock Forecast | ICU Medical | Outperform |
16
|
$191.97 | $213.00 | 12.52% |
| HAE Stock Forecast | Haemonetics | Hold |
16
|
$88.35 | $70.17 | -2.09% |
Fresenius SE & Co. KGaA EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's EPS has seen a drop from 3.44€ to 3.35€ – a 2.62% decrease. According to 0 major analysts, Fresenius SE & Co. KGaA's EPS will fall by 0.31% in the next year, reaching 3.34€. Professionals believe that By 2030, Fresenius SE & Co. KGaA's EPS will fall to 3.34€– a 0.40% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LIVN Stock Forecast | LivaNova PLC | Outperform |
12
|
$45.72 | $0.00 | 116.54% |
| 500680 Stock Forecast | Pfizer | Buy |
18
|
Rp4.35k | Rp6.10k | 21.27% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$7.10 | $34.09 | 5.63% |